Harpoon Therapeutics Appoints Haibo Wang as Senior Vice President of Business Development

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced the appointment of Haibo Wang as Senior Vice President of Business Development. Mr. Wang brings 15 years of biopharma business development, finance, and mergers and acquisitions (M&A) transaction experience to Harpoon.

"We are pleased to welcome Haibo as Senior Vice President of Business Development at Harpoon,” said Julie Eastland, President and CEO of Harpoon Therapeutics. “Haibo's extensive experience and strategic acumen will play a pivotal role in driving our business growth and forging impactful partnerships. We are confident that his expertise and understanding of targets such as BCMA and DLL3 will contribute significantly to our mission to transform cancer treatment through the power of T cell engagers."

Mr. Wang most recently served as Vice President of Business Development at Hummingbird Bioscience where he was responsible for the company’s end-to-end business development activities. Prior to Hummingbird, Mr. Wang was Director of Business Development at Amgen, where he played a major role in the Teneobio and Five Prime Therapeutics acquisitions, the oncology collaboration with BeiGene, and many clinical collaborations to advance Amgen’s oncology pipeline. Prior to Amgen, Mr. Wang was an M&A consultant at Deloitte, advising on numerous transactions in the healthcare and tech sectors in China. He received his M.S. in Biotechnology from Johns Hopkins University, MBA from Duke University, and B.S. from Tsinghua University.

Inducement Award under NASDAQ Listing Rule 5635(c)(4)

In connection with Mr. Wang’s appointment, Harpoon Therapeutics granted him an inducement non-qualified stock option to purchase an aggregate of 200,000 shares of Harpoon’s common stock.

The stock option grant has an exercise price per share equal to $0.78, Harpoon’s closing trading price on Nasdaq on the grant date, July 31, 2023, and will vest over four years, with 1/4 of the underlying shares vesting on the one-year anniversary of the grant date and the remainder of the underlying shares vesting monthly thereafter in equal installments over 36 months, subject to his continued service relationship with Harpoon through the applicable vesting dates.